Immucell Stock Current Asset
| ICCC Stock | USD 3.69 0.03 0.82% |
ImmuCell fundamentals help investors to digest information that contributes to ImmuCell's financial success or failures. It also enables traders to predict the movement of ImmuCell Stock. The fundamental analysis module provides a way to measure ImmuCell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImmuCell stock.
The current year's Non Current Assets Total is expected to grow to about 34 M, whereas Other Current Assets are forecasted to decline to about 247.6 K. ImmuCell | Current Asset |
ImmuCell Company Current Asset Analysis
ImmuCell's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current ImmuCell Current Asset | 4.49 M |
Most of ImmuCell's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmuCell is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ImmuCell Current Asset Historical Pattern
Today, most investors in ImmuCell Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ImmuCell's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of ImmuCell current asset as a starting point in their analysis.
ImmuCell Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
ImmuCell Total Assets
Total Assets |
|
In accordance with the recently published financial statements, ImmuCell has a Current Asset of 4.49 M. This is 99.79% lower than that of the Biotechnology sector and 99.58% lower than that of the Health Care industry. The current asset for all United States stocks is 99.95% higher than that of the company.
ImmuCell Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmuCell's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ImmuCell could also be used in its relative valuation, which is a method of valuing ImmuCell by comparing valuation metrics of similar companies.ImmuCell is currently under evaluation in current asset category among its peers.
ImmuCell ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ImmuCell's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ImmuCell's managers, analysts, and investors.Environmental | Governance | Social |
ImmuCell Fundamentals
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0487 | ||||
| Profit Margin | (0.17) % | ||||
| Operating Margin | (0.25) % | ||||
| Current Valuation | 44.61 M | ||||
| Shares Outstanding | 8.91 M | ||||
| Shares Owned By Insiders | 39.52 % | ||||
| Shares Owned By Institutions | 14.51 % | ||||
| Number Of Shares Shorted | 4.01 K | ||||
| Price To Earning | 195.00 X | ||||
| Price To Book | 1.25 X | ||||
| Price To Sales | 1.42 X | ||||
| Revenue | 17.47 M | ||||
| Gross Profit | 7.65 B | ||||
| EBITDA | (2.5 M) | ||||
| Net Income | (5.77 M) | ||||
| Cash And Equivalents | 11.04 M | ||||
| Cash Per Share | 1.43 X | ||||
| Total Debt | 16.69 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 6.91 X | ||||
| Book Value Per Share | 3.23 X | ||||
| Cash Flow From Operations | (4.67 M) | ||||
| Short Ratio | 0.23 X | ||||
| Earnings Per Share | (0.49) X | ||||
| Target Price | 14.0 | ||||
| Number Of Employees | 75 | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 32.08 M | ||||
| Total Asset | 43.81 M | ||||
| Retained Earnings | (12.01 M) | ||||
| Working Capital | 10.92 M | ||||
| Current Asset | 4.49 M | ||||
| Current Liabilities | 258.78 K | ||||
| Net Asset | 43.81 M |
About ImmuCell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImmuCell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmuCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmuCell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:Check out ImmuCell Piotroski F Score and ImmuCell Altman Z Score analysis. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.49) | Revenue Per Share 2.991 | Quarterly Revenue Growth 0.549 | Return On Assets (0.05) |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.